Annovis Bio Presents Groundbreaking Research at CTAD 2025
In a significant development for the field of neurodegenerative diseases, Annovis Bio, Inc. (NYSE: ANVS), a pioneering company in transforming therapies for conditions like Alzheimer’s disease and Parkinson’s disease, recently announced their participation at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference. This event is scheduled for the beginning of December with the location set in San Diego, California.
The presentations will unveil the latest advancements in research, emphasizing the encouraging biomarker data that underscores the potential disease-modifying capabilities of their leading product, buntanetap.
Details of the Presentations
The company will present two pivotal studies at the conference, focusing on the implications of their groundbreaking work in Alzheimer’s and Parkinson’s treatments.
First Presentation Overview
Presentation #1 will delve into the association between amyloid co-pathology and cognitive decline among patients with Parkinson’s disease who have been treated with buntanetap. This session will feature insights from Cheng Fang, Ph.D., who holds the position of Senior VP of Research & Development. Attendees can expect a compelling discussion that highlights the advancements made in this critical area of study.
Second Presentation Overview
Presentation #2, delivered by Maria Maccecchini, Ph.D., the President and CEO, will focus on a comprehensive 6/18-month Phase 3 study. This study aims to replicate previously observed symptomatic improvements while exploring the potential disease-modifying efficacy of buntanetap in Alzheimer's patients. Both presentations are scheduled to take place around the same time, starting on December 1 and continuing into December 2.
Excitement for the Event
Maria Maccecchini expressed enthusiasm for attending the CTAD event, stating, "This conference provides an ideal opportunity to share our latest findings regarding biomarkers and cognitive function with the broader scientific community. Our research brings forward exciting possibilities that resonate profoundly with clinicians, researchers, and industry experts alike. Our biomarker data illustrates a compelling narrative—buntanetap may effectively tackle the fundamental causes of cognitive decline."
Maccecchini emphasized that the results not only confirm the efficacy previously noted in earlier trials but also chart a clearer course in their mission to deliver effective treatments to patients who desperately seek better therapeutic options.
About Annovis Bio
Headquartered in Malvern, Pennsylvania, Annovis Bio is devoted to innovating in the neurodegeneration space, particularly regarding diseases such as Alzheimer's and Parkinson's. The company’s commitment extends towards developing therapies aimed at enhancing patient outcomes and quality of life. To learn more about their advances and research initiatives, visit their official website.
Contact Information
If you would like to get in touch with Annovis Bio to learn more about their work or for investor inquiries, the contact information is as follows:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
Frequently Asked Questions
What is the primary focus of Annovis Bio?
Annovis Bio is focused on developing transformative therapies for neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s diseases.
What will be highlighted during the CTAD presentations?
The presentations will showcase the latest findings related to biomarker data and the efficacy of bunsanetap in treating cognitive decline.
Who are the key presenters at the event?
Cheng Fang, Ph.D., and Maria Maccecchini, Ph.D., will lead the presentations, covering significant research aspects of the company's treatment methodologies.
What is buntanetap?
Buntanetap is an investigational treatment that targets the underlying causes of cognitive decline in neurodegenerative diseases.
How can investors receive updates on Annovis Bio?
Interested investors can sign up for press releases and industry updates on the Annovis Bio website by registering for email alerts.